Pharma MarPHMMF -3.64%82 Return-on-Tangible-Asset is 1.58% as of Mar. 2026, which is 60% below its 10-year median of 3.96. GuruFocus rates PHMMF with a GF Score™ of 82/100 and a GF Value™ of $94.75 (Fairly Valued). The stock has 3 warning signs investors should review. Among 1,413 Biotechnology companies, Pharma Mar ranks better than 95.68% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Pharma Mar's annualizedNet Income for the quarter that ended in Mar. 2026 was $7.1 Mil. Pharma Mar's average total tangible assets for the quarter that ended in Mar. 2026 was $449.7 Mil. Therefore, Pharma Mar's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was 1.58%.
The historical rank and industry rank for Pharma Mar's Return-on-Tangible-Asset or its related term are showing as below:
PHMMF'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -14.91 Med: 3.96 Max: 61.69
Current: 21.3
During the past 13 years, Pharma Mar's highest Return-on-Tangible-Asset was 61.69%. The lowest was -14.91%. And the median was 3.96%.
PHMMF's Return-on-Tangible-Asset is ranked better than 95.68% of 1413
companies
in the Biotechnology industry
Industry Median: -35.77
vs PHMMF: 21.30
Pharma Mar (OTCPK:PHMMF) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Pharma Mar Return-on-Tangible-Asset Related Terms
Pharma Mar Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Pharma Mar's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PHMMF vs VRTX, REGN, ALNY: Return-on-Tangible-Asset Comparison
For the Biotechnology subindustry, Pharma Mar's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pharma Mar Return-on-Tangible-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Pharma Mar's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Pharma Mar's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of 1.58% mean?
Pharma Mar (PHMMF) has a Return-on-Tangible-Asset of 1.58% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Pharma Mar and its competitors. This is 60% below median its historical median of 3.96. According to the industry distribution chart, Pharma Mar ranks #61 out of 1413 companies in the Biotechnology industry, placing it in the top 4.3%.
Is Pharma Mar's Return-on-Tangible-Asset too high?
Pharma Mar's current Return-on-Tangible-Asset of 1.58% is 60% below median its 10-year median of 3.96. Based on the distribution chart, Pharma Mar ranks #61 out of 1413 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Pharma Mar has a GF Score™ of 82/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Pharma Mar's Return-on-Tangible-Asset compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Pharma Mar ranks #61 out of 1413 companies for Return-on-Tangible-Asset. This places Pharma Mar in the top 4% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Biotechnology company?
A good Return-on-Tangible-Asset depends on the Biotechnology industry context. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Pharma Mar and its competitors. Pharma Mar's current Return-on-Tangible-Asset is 1.58%, which is 60% below median its own 10-year median of 3.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharma Mar stock overvalued right now?
Based on GuruFocus' analysis, Pharma Mar (PHMMF) is currently considered Fairly Valued. The stock's GF Value™ is $94.75, compared to a current price of $90.90 — trading 4.1% below its estimated fair value. The current Return-on-Tangible-Asset is 1.58%, which is 60% below median its 10-year median of 3.96. Pharma Mar's overall GF Score™ is 82/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Pharma Mar (PHMMF), the current Return-on-Tangible-Asset is 1.58% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pharma Mar (PHMMF) Overvalued in 2026?
Based on GuruFocus' analysis, Pharma Mar stock appears to be undervalued.
The current stock price of $90.90 is trading 4.1% below its estimated GF Value™ of $94.75.
GuruFocus considers Pharma Mar to be Fairly Valued.
Key valuation signals for PHMMF:
Return-on-Tangible-Asset: 1.58% (60% below median its 10-year median of 3.96)
GF Value™: $94.75 vs. price of $90.90 (4.1% below fair value)
No single metric tells the full story. See the PHMMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pharma Mar SA is engaged in the research, development, production, and commercialization of bio-active principles of marine origin for application in oncology. It also produces and markets insecticides and air fresheners for household use, household products, wood treatment and decoration products, paints, and similar products. Its operating business segments are Oncology and RNAi. The company obtains its revenues from two main areas: biopharmaceuticals and consumer chemicals, but the biopharmaceuticals is the main line of business.
82GF Score
Get the complete analysis for PHMMF
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PHMMF has been successfully added to your 
